Metabolic control in type 2 diabetic patients treated with empagliflozin: A case series

Estudios originales

Published on 17 de abril de 2024 | http://doi.org/10.5867/medwave.2024.03.2758

Metabolic control in type 2 diabetic patients treated with empagliflozin: A case series

Comparison of pre and post treatment variables with empagliflozin in different periods of time.

	n	HbA1c	Standard deviation	Mean difference versus baseline	95% CI	p value
Baseline¹	58	10.3	1.63	(-)	(-)	(-)
Less than 6 months	40	8.71	1.3	-1.78	1.39 to 2.18	< 0.0001
6 to 12 months	53	8.5	1.7	-1.82	1.41 to 2.23	< 0.0001
12 to 18 months	45	8.81	1.8	-1.52	0.94 to 2.1	< 0.0001
18 to 24 months	22	8.98	2.2	-1.27	0.5 to 2.03	0.002

1Follow-up of 19 (16.3 to 40) months.

Abbreviations HbA1c, glycosylated hemoglobin A1c. CI, confidence interval. SD, standard deviation.

Source: Prepared by the authors of this study.